Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2440388 | 0.96 | LMNA (0.52) | LMNAL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7063863 | 0.95 | LMNA (0.51) | LMNAL3MBTL1ALDH1A1XDH | |
| SCHEMBL7063685 | 0.95 | LMNA (0.51) | LMNAL3MBTL1ALDH1A1XDH | |
| SCHEMBL7062391 | 0.92 | LMNA (0.42) | LMNAL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7063733 | 0.86 | ALDH1A1 (0.43) | RAB9ANPC1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL3825844 | 0.80 | LMNA (0.41) | LMNAL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7062253 | 0.78 | KDM4E (0.36) | LMNANPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL18325610 | 0.77 | XDH (0.50) | LMNAL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2651522 | 0.76 | L3MBTL1 (0.46) | LMNAL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12894748 | 0.76 | EPHX2 (0.50) | LMNASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166606-A1 | 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients | KOLON INDUSTRIES, INC. (KR) | 2003-09-04 | — | — | US | disclosed |
| EP-1311524-A2 | 5'-DEOXY-N-(SUBSTITUTED OXYCARBONYL)-5-FLUOROCYTOSINE AND DERIVATIVES THEREOF, METHOD OF PREPARING SAME, AND ANTICANCER COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENTS | Kolon Industries, Inc. (KR) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002011668-A2 | 5'-DEOXY-N-(SUBSTITUTED OXYCARBONYL)-5-FLUOROCYTOSINE AND DERIVATIVES THEREOF, METHOD OF PREPARING SAME, AND ANTICANCER COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENTS | KOLON INDUSTRIES, INC. (KR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166606-A1 | 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients | DUT, RNGTT, MTAP | LMNA 3178/4885L3MBTL1 4214/4885RAB9A 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.